Results 221 to 230 of about 3,067,377 (342)

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ...
Young Nam Kwon   +24 more
wiley   +1 more source

If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives Intravenous immunoglobulin (IVIg) is an effective treatment for Guillain–Barré syndrome (GBS), but recovery varies between patients. This study aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of a single and a second IVIg dose (SID) in patients with GBS.
Sander J. van Tilburg   +7 more
wiley   +1 more source

Prevalence of impairments, disabilities, handicaps and quality of life in the general population: a review of recent literature.

open access: green, 2001
E. Barbotte   +21 more
openalex   +1 more source

Clinical impact and safety of brain biopsy in unexplained central nervous system disorders: a real‐world cohort study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objective A substantial part of central nervous system (CNS) disorders remains unexplained, despite various new and minimally invasive diagnostic techniques. Within this rapidly developing diagnostic field, the precise role of brain biopsy is unknown.
Robin W. van Steenhoven   +14 more
wiley   +1 more source

ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objective We performed a pilot screen to assess the utility of the NULISA™ (Nucleic‐acid‐Linked Immuno‐Sandwich Assay) platform in the identification of amyotrophic lateral sclerosis (ALS) biomarkers. Methods Plasma from 86 individuals (48 ALS, 18 asymptomatic C9orf72 repeat expansion carriers (AsymC9), and 20 healthy controls) was analyzed ...
Eleanor V. Thomas   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy